Orphan Drug

What is Orphan Drug Designation?

Orphan drug designation is a special regulatory status granted to drugs developed for rare diseases. The designation provides financial incentives and regulatory benefits to encourage development of treatments for conditions that affect too few patients to be commercially attractive under normal circumstances. For peptide researchers, orphan designation can make development of niche therapeutics economically feasible.

The Orphan Drug Act (1983) was created because:

• Rare disease patients were “orphaned” by the pharmaceutical industry
• Small markets couldn’t justify development costs
• No financial incentive existed to pursue rare disease treatments
• Patients had no hope for approved therapies

Qualifying for Orphan Designation

Prevalence Criteria

Region	Threshold	Definition
United States	Under 200,000 patients	Or no reasonable expectation of cost recovery
European Union	Under 5 per 10,000	Plus serious/life-threatening condition
Japan	Under 50,000 patients	Or especially difficult to treat

Application Requirements

To obtain orphan designation, sponsors must demonstrate:

1. Disease identification - Clearly defined condition
2. Prevalence data - Below threshold population
3. Scientific rationale - Plausible mechanism for treatment
4. Development status - Intent to develop for the condition

Benefits of Orphan Designation

Financial Incentives

Benefit	Details
Tax credits	25% of qualified clinical trial expenses (US)
Fee waivers	Reduced or waived FDA application fees
Grant funding	FDA Orphan Products Grants Program
Protocol assistance	Free scientific advice from regulators

Regulatory Advantages

Benefit	Impact
Market exclusivity	7 years (US), 10 years (EU)
Expedited review	Potential priority review
Rolling submission	Submit portions as completed
Smaller trials	Reduced patient requirements may apply

Market Exclusivity

Orphan exclusivity prevents FDA from approving another version of the same drug for the same indication:

Orphan Drug Approved
        ↓
7-Year Exclusivity Period (US)
├── No generic approval
├── No biosimilar approval
└── Exception: Clinical superiority
        ↓
Exclusivity Expires
        ↓
Competition Possible

Peptide Orphan Drugs

Approved Peptide Orphan Drugs

Drug	Brand	Orphan Indication	Approval
Tesamorelin	Egrifta	HIV lipodystrophy	2010
Setmelanotide	Imcivree	POMC/LEPR obesity	2020
Pasireotide	Signifor	Cushing’s disease	2012
Metreleptin	Myalept	Lipodystrophy	2014
Lanreotide	Somatuline	Acromegaly, NETs	Various

Peptides with Orphan Designation in Development

Multiple peptide candidates hold orphan designation for conditions including:

• Rare metabolic disorders
• Rare endocrine conditions
• Rare genetic syndromes affecting peptide signaling
• Orphan oncology indications

Orphan Drug Development Process

Typical Timeline

Identify Rare Disease Target
            ↓
Request Orphan Designation (any time before NDA)
            ↓
FDA Review (90 days)
            ↓
Designation Granted
            ↓
Development with Incentives
├── Tax credits for trials
├── Protocol assistance
└── Grant funding available
            ↓
NDA/BLA Submission
            ↓
Approval + 7-Year Exclusivity

Clinical Trial Considerations

Aspect	Standard Drug	Orphan Drug
Patient enrollment	Large trials feasible	Small pool, difficult recruitment
Geographic scope	Regional possible	Often global required
Endpoint design	Standard endpoints	May use surrogate endpoints
Statistical approach	Traditional power	Adaptive designs, Bayesian
Placebo use	Common	Ethical concerns in rare diseases

Criticism and Controversies

”Orphan Drug” for Common Conditions

Some companies have sought orphan designation for subsets of common diseases:

• Specific genetic subtypes of obesity
• Rare forms of diabetes
• Pediatric subpopulations

This practice, sometimes called “salami slicing,” is controversial.

Pricing Concerns

Concern	Reality
High prices	Orphan drugs average >$150,000/year
Small market justification	Some orphan drugs earn billions
Access barriers	Insurance may deny coverage
Global disparities	Many countries can’t afford access

Proposed Reforms

• Require price justification for exclusivity
• Limit exclusivity extension through new indications
• Increase prevalence reporting requirements
• Tie incentives to actual development costs

Orphan Designation vs Other Expedited Programs

Program	Purpose	Exclusivity
Orphan	Rare diseases	7 years
Fast Track	Serious conditions, unmet need	None
Breakthrough	Substantial improvement	None
Priority Review	Significant advance	None
Accelerated Approval	Surrogate endpoints	None

These designations can be combined. An orphan drug may also receive breakthrough therapy designation and priority review.

International Orphan Drug Programs

European Union

• Similar structure to US program
• 10-year market exclusivity (vs 7 in US)
• Protocol assistance available
• Administered by EMA

Japan

• Orphan drug designation since 1993
• 10-year exclusivity
• Priority review
• Subsidized development costs

Harmonization Efforts

Regulators increasingly coordinate:

• Common application formats
• Simultaneous designation possible
• Shared scientific advice
• Joint development programs

Frequently Asked Questions

Can a drug lose orphan status?

Orphan designation can be revoked if the disease is later found to affect more than 200,000 people, or if the sponsor no longer intends to develop the drug for the orphan indication. Market exclusivity can be lost if clinical superiority of a competitor is demonstrated.

Do orphan drugs have to be expensive?

No regulatory requirement mandates high prices. However, small markets and high development costs often result in premium pricing. Some companies have faced criticism for pricing orphan drugs at levels exceeding what small market size would justify.

Can existing drugs get orphan designation?

Yes. A drug approved for a common condition can receive orphan designation for a new rare disease indication. This provides exclusivity only for the orphan indication, not the original use.

What happens after exclusivity expires?

Generic or biosimilar competition becomes possible. However, many orphan drugs maintain market position due to physician familiarity, limited competition interest in small markets, and manufacturing complexity.